(Q57222268)

English

Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane

scientific article published on 09 August 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25107569%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25107569%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

metastatic breast cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25107569%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25107569%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25107569%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25107569%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25107569%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25107569%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25107569%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Hyun Cheol Chung

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25107569%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Hei Cheul Jeung

2

object named as

Hei-Cheul Jeung

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25107569%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

9

object named as

Woo Ick Yang

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25107569%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

8

object named as

Seungtaek Lim

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25107569%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

language of work or name

0 references

publication date

9 August 2014

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25107569%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25107569%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

74

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25107569%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25107569%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

799-808

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25107569%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

https://scigraph.springernature.com/pub.10.1007/s00280-014-2551-4

0 references

A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2551-4

21 January 2018

Treatment of metastatic breast cancer: second line and beyond

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2551-4

21 January 2018

Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193).

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2551-4

21 January 2018

Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2551-4

21 January 2018

Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2551-4

21 January 2018

A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2551-4

21 January 2018

Capecitabine monotherapy: safe and effective treatment for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2551-4

21 January 2018

Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2551-4

21 January 2018

Efficacy and safety of single agent capecitabine in pretreated metastatic breast cancer patients from the French compassionate use program.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2551-4

21 January 2018

Anti-tumor activity of capecitabine and vinorelbine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: findings from the EORTC 10001 randomized phase II trial

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2551-4

21 January 2018

Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2551-4

21 January 2018

Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a phase I/II trial

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2551-4

21 January 2018

Gemcitabine/capecitabine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2551-4

21 January 2018

Gemcitabine plus capecitabine combination in metastatic breast cancer patients previously treated with anthracyclines and taxanes

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2551-4

21 January 2018

Gemcitabine and capecitabine in combination for advanced anthracycline and taxane pre-treated breast cancer patients: A phase II study

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2551-4

21 January 2018

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2551-4

21 January 2018

Sample size tables for exact single-stage phase II designs

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2551-4

21 January 2018

Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2551-4

21 January 2018

Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2551-4

21 January 2018

American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2551-4

21 January 2018

Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast cancer: a multicenter phase II study (SOLTI 0301 trial).

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2551-4

21 January 2018

Capecitabine for the treatment for advanced gastric cancer: efficacy, safety and ethnicity

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2551-4

21 January 2018

Dose-adjusting capecitabine minimizes adverse effects while maintaining efficacy: a retrospective review of capecitabine for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2551-4

21 January 2018

Identifiers

10.1007/S00280-014-2551-4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25107569%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25107569%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57222268&oldid=2097264446"